Potent 2420-Class of Protease Inhibitors for Treatment of COVID-19

  • TRL
  • 2

Purdue University researchers have developed a series of compounds for the treatment of COVID-19, the respiratory illness caused by the SARS-CoV-2 coronavirus strain. While a few COVID-19 treatments have been approved for emergency use, such treatments are limited to patients with mild to moderate COVID-19 symptoms or disease recurrence occur after completing the treatment course. The Purdue compounds potently inhibit the SARS-CoV-2 3C-like protease (3CL-pro) and block SARS-CoV-2 replication in vitro. The researchers expect these compounds and their derivatives to possess drug-like properties. Advantages: -Potent inhibitor of SARS-CoV-2 3CL-pro enzyme -Blocks SARS-CoV-2 viral replication Applications: -COVID-19 treatment -Drug discovery

Contact Information

Name: Joseph R Kasper

Email: JRKasper@prf.org

Phone: 765-588-3475